$199.39
0.43% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
US46266C1053
Symbol
IQV

IQVIA Stock price

$199.39
-2.04 1.01% 1M
-13.36 6.28% 6M
-31.99 13.83% YTD
-32.53 14.03% 1Y
-82.67 29.31% 3Y
+44.95 29.11% 5Y
+139.44 232.59% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.86 0.43%
ISIN
US46266C1053
Symbol
IQV
Sector

Key metrics

Market capitalization $36.19b
Enterprise Value $48.18b
P/E (TTM) P/E ratio 26.15
EV/FCF (TTM) EV/FCF 24.57
EV/Sales (TTM) EV/Sales 3.15
P/S ratio (TTM) P/S ratio 2.36
P/B ratio (TTM) P/B ratio 5.20
Revenue growth (TTM) Revenue growth 3.17%
Revenue (TTM) Revenue $15.31b
EBIT (operating result TTM) EBIT $2.16b
Free Cash Flow (TTM) Free Cash Flow $1.96b
Cash position $1.71b
EPS (TTM) EPS $7.62
P/E forward 27.82
P/S forward 2.35
EV/Sales forward 3.13
Short interest 1.77%
Show more

Is IQVIA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

IQVIA Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a IQVIA forecast:

24x Buy
86%
4x Hold
14%

Analyst Opinions

28 Analysts have issued a IQVIA forecast:

Buy
86%
Hold
14%

Financial data from IQVIA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
15,314 15,314
3% 3%
100%
- Direct Costs 11,055 11,055
2% 2%
72%
4,259 4,259
6% 6%
28%
- Selling and Administrative Expenses 968 968
6% 6%
6%
- Research and Development Expense - -
-
-
3,291 3,291
7% 7%
21%
- Depreciation and Amortization 1,127 1,127
3% 3%
7%
EBIT (Operating Income) EBIT 2,164 2,164
13% 13%
14%
Net Profit 1,405 1,405
26% 26%
9%

In millions USD.

Don't miss a Thing! We will send you all news about IQVIA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IQVIA Stock News

Neutral
Business Wire
6 days ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions tha...
Neutral
Seeking Alpha
17 days ago
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term r...
Neutral
Business Wire
about 2 months ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations ...
More IQVIA News

Company Profile

Provides biopharmaceutical development services and commercial outsourcing services

Head office United States
CEO Ari Bousbib
Employees 87,000
Founded 1950
Website www.iqvia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today